Cytokines

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Biology, Cytokines, Idiopathic pulmonary fibrosis, Ifenprodil, IPF, Pulmonary fibrosis, Interleukin 6, COVID-19, Myokine, Cytokine, Cough

b'VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.\xc2\xa0(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAlgernon\xe2\x80\x9d) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial, which may be informative for the Company\xe2\x80\x99s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough.\nThe Company reports that in the COVID-19 trial, one of the biomarkers that was measured was the change in IL-6 levels.

Key Points: 
  • b'VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.\xc2\xa0(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAlgernon\xe2\x80\x9d) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial, which may be informative for the Company\xe2\x80\x99s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough.\nThe Company reports that in the COVID-19 trial, one of the biomarkers that was measured was the change in IL-6 levels.
  • In the measurement from baseline to day five, IL-6 was reduced in the 20 mg treatment arm by 267 ng/L, versus 7 ng/L in the standard of care arm (values are adjusted mean concentrations; p = 0.0292).\nIL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine and is encoded by the IL-6 gene.
  • IL-6 can promote fibrosis by driving chronic inflammation and is elevated in patients with IPF.1 Blockade of IL-6 has been shown to attenuate pulmonary fibrosis in a mouse model.2\nThe effects of Ifenprodil on IL-6 may be helpful in better understanding its potential role as a possible therapeutic treatment for IPF.\nThe company recently announced it had achieved 50% of its enrollment target for its Phase 2 trial of Ifenprodil for IPF and chronic cough.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.\n'

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Cytokines, Chemokine receptors, Clusters of differentiation, C-C chemokine receptor type 7, CCL21, Angiology, Dendritic cell, Neuropilin 2, Forward-looking statement, Lymphatic system

\xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.

Key Points: 
  • \xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.
  • In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs.
  • All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain.
  • Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n'

Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Biology, Interleukins, Cell biology, Cytokines, Immune system, Lymphatic system, T helper cell, Inflammatory cytokine, Cytokine

Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.

Key Points: 
  • Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.
  • Type 2 inflammation is mediated by type 2 helper T-cells (TH2), which secrete inflammatory cytokines including IL-3, IL-4, L-5, IL-9 and IL-13.
  • The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved.
  • This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\n'

HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, May 12, 2021
Medical specialties, Clinical medicine, Medicine, Cytokines, Antiviral drugs, Immunology, Cancer immunotherapy, Immunotherapy, Virotherapy, Cytokine, Interferon, Immune system

\xe2\x80\x9cWe believe these data are impressive, and they are consistent with the pre-clinical data published in Cell Reports Medicine in March.

Key Points: 
  • \xe2\x80\x9cWe believe these data are impressive, and they are consistent with the pre-clinical data published in Cell Reports Medicine in March.
  • Both data sets highlight the potential of our engineered arenavirus platform to redefine success in cancer immunotherapy.
  • Early HB-201 monotherapy data also highlighted immune system activation of increasing interferon-gamma and other immune stimulatory cytokines with a single dose.
  • It is possible that the information we post on social media could be deemed to be material information.

Organicell Receives Approval in Pakistan for the Use of Zofin™ for Compassionate Grounds for COVID-19

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Branches of biology, Biology, Chemokine, Cytokines, Signal transduction, Cytokine, Vesicle

Treatment with Zofin\xe2\x84\xa2 will take place at the Pakistan Institute of Medical Sciences (PIMS).

Key Points: 
  • Treatment with Zofin\xe2\x84\xa2 will take place at the Pakistan Institute of Medical Sciences (PIMS).
  • This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.
  • Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005306/en/\n'

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Life sciences, Health sciences, Pharmaceutical industry, Biotechnology, Immunology, Cytokines, Tumor necrosis factor, Uveitis, Biopharmaceutical, Contract manufacturing organization, Inflammation

b'Seattle, May 06, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.\n\xe2\x80\x9cWe are very pleased that Oculis has chosen us to manufacture this treatment,\xe2\x80\x9d says AGC Biologics Chief Business Officer, Mark Womack.

Key Points: 
  • b'Seattle, May 06, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.\n\xe2\x80\x9cWe are very pleased that Oculis has chosen us to manufacture this treatment,\xe2\x80\x9d says AGC Biologics Chief Business Officer, Mark Womack.
  • \xe2\x80\x9cOur Heidelberg site has the experience and expertise to deliver this program from early phase to market.\xe2\x80\x9d\nOCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor.
  • TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.
  • We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.

Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection

Retrieved on: 
Wednesday, May 5, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Cytokines, Interferon, Severe acute respiratory syndrome, Medical specialties, Infectious diseases, Branches of biology, REVTx‑99, REVDx‑501, Revelation Biosciences Inc., REVTX‑99, REVDX‑501, REVELATION BIOSCIENCES INC.

b'Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today results from RVL\xe2\x80\x91NHV01, a Phase 1 clinical study of REVTx-99.

Key Points: 
  • b'Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today results from RVL\xe2\x80\x91NHV01, a Phase 1 clinical study of REVTx-99.
  • Secondary and exploratory endpoints comprised change in serum cytokine levels, treatment emergent adverse events and plasma PK levels.\nRevelation plans to initiate a Phase 2 viral challenge study to evaluate the potential utility of REVTx\xe2\x80\x9199 for preventing and treating respiratory viral infection.
  • Influenza and SARS\xe2\x80\x91CoV\xe2\x80\x912 have viral proteins that have been shown to block the production of interferons, a key part of the innate immune response to viral infection, resulting in worsened clinical outcomes.
  • Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made.

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Retrieved on: 
Tuesday, May 4, 2021
Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Antineoplastic drugs, Cytokines, Biopharmaceutical, Pharmacy, Medication, Histone deacetylase inhibitor, Macrophage colony-stimulating factor

b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Tuesday, May 11, to discuss the Company\'s financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company\'s website at www.syndax.com .
  • The Company\'s pipeline includes SNDX-5613, a highly selective inhibitor of the MeninMLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .\n'

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Medicine, Clinical medicine, Transplantation medicine, Hematology, Stem cells, Cytokines, Growth factors, Granulocyte colony-stimulating factor, Apheresis, Autologous stem-cell transplantation, Organ transplantation

The addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm an 8.2-fold increase.

Key Points: 
  • The addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm an 8.2-fold increase.
  • "This is a great achievement in alleviating the burden for the patients and reducing hospital resources.
  • I believe these results make the combination of Motixafortide and G-CSF a very attractive candidate for use in all patients with multiple myeloma undergoing autologous stem-cell transplantation.
  • "\n"These strikingly positive data significantly exceeded our expectations, and are truly transformational for our company," stated Philip Serlin, Chief Executive Officer of BioLineRx.

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

Retrieved on: 
Friday, April 30, 2021
Cytokines, Medical specialties, Branches of biology, Medicine, Antiviral drugs, Zoonoses, Bat virome, Interferon beta-1a, Interferon, COVID-19, Severe acute respiratory syndrome

A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.

Key Points: 
  • A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.
  • In parallel with the Phase III trial in the hospital setting, there is now an urgent need to assess SNG001 in the non-hospital setting, focussing entirely on breathless COVID-19 patients.
  • Please find a link to this webcast here.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No.
  • 596/2014 (\xe2\x80\x98MAR\xe2\x80\x99).\nThe Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial".